vs
阿特拉斯·科普柯（AESI）与Apellis Pharmaceuticals, Inc.（APLS）财务数据对比。点击上方公司名可切换其他公司
阿特拉斯·科普柯的季度营收约是Apellis Pharmaceuticals, Inc.的1.2倍（$249.4M vs $199.9M），阿特拉斯·科普柯净利率更高（-8.9% vs -29.5%，领先20.6%），Apellis Pharmaceuticals, Inc.同比增速更快（-5.9% vs -8.1%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-18.1M），过去两年阿特拉斯·科普柯的营收复合增速更高（13.8% vs 7.7%）
阿特拉斯·科普柯集团是瑞典跨国工业企业，生产压缩机、真空设备、泵、发电机、装配工具、质量检测设备等工业应用及移动发电领域的产品与系统，业务覆盖全球约180个国家。
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
AESI vs APLS — 直观对比
营收规模更大
AESI
是对方的1.2倍
$199.9M
营收增速更快
APLS
高出2.1%
-8.1%
净利率更高
AESI
高出20.6%
-29.5%
自由现金流更多
APLS
多$3.8M
$-18.1M
两年增速更快
AESI
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $249.4M | $199.9M |
| 净利润 | $-22.2M | $-59.0M |
| 毛利率 | 8.1% | — |
| 营业利润率 | -6.0% | -25.6% |
| 净利率 | -8.9% | -29.5% |
| 营收同比 | -8.1% | -5.9% |
| 净利润同比 | -254.5% | -62.2% |
| 每股收益（稀释后） | $-0.19 | $-0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AESIAPLS
| Q4 25 | $249.4M | $199.9M | ||
| Q3 25 | $259.6M | $458.6M | ||
| Q2 25 | $288.7M | $178.5M | ||
| Q1 25 | $297.6M | $166.8M | ||
| Q4 24 | $271.3M | $212.5M | ||
| Q3 24 | $304.4M | $196.8M | ||
| Q2 24 | $287.5M | $199.7M | ||
| Q1 24 | $192.7M | $172.3M |
净利润AESIAPLS
| Q4 25 | $-22.2M | $-59.0M | ||
| Q3 25 | $-23.7M | $215.7M | ||
| Q2 25 | $-5.6M | $-42.2M | ||
| Q1 25 | $1.2M | $-92.2M | ||
| Q4 24 | $14.4M | $-36.4M | ||
| Q3 24 | $3.9M | $-57.4M | ||
| Q2 24 | $14.8M | $-37.7M | ||
| Q1 24 | $26.8M | $-66.4M |
毛利率AESIAPLS
| Q4 25 | 8.1% | — | ||
| Q3 25 | 9.2% | — | ||
| Q2 25 | 18.1% | — | ||
| Q1 25 | 18.3% | — | ||
| Q4 24 | 18.4% | — | ||
| Q3 24 | 17.4% | — | ||
| Q2 24 | 21.0% | — | ||
| Q1 24 | 35.7% | — |
营业利润率AESIAPLS
| Q4 25 | -6.0% | -25.6% | ||
| Q3 25 | -7.1% | 48.7% | ||
| Q2 25 | 2.5% | -18.6% | ||
| Q1 25 | 5.2% | -50.0% | ||
| Q4 24 | 11.3% | -12.3% | ||
| Q3 24 | 5.0% | -24.0% | ||
| Q2 24 | 9.8% | -14.7% | ||
| Q1 24 | 20.6% | -36.0% |
净利率AESIAPLS
| Q4 25 | -8.9% | -29.5% | ||
| Q3 25 | -9.1% | 47.0% | ||
| Q2 25 | -1.9% | -23.6% | ||
| Q1 25 | 0.4% | -55.3% | ||
| Q4 24 | 5.3% | -17.1% | ||
| Q3 24 | 1.3% | -29.2% | ||
| Q2 24 | 5.2% | -18.9% | ||
| Q1 24 | 13.9% | -38.5% |
每股收益（稀释后）AESIAPLS
| Q4 25 | $-0.19 | $-0.40 | ||
| Q3 25 | $-0.19 | $1.67 | ||
| Q2 25 | $-0.04 | $-0.33 | ||
| Q1 25 | $0.01 | $-0.74 | ||
| Q4 24 | $0.12 | $-0.30 | ||
| Q3 24 | $0.04 | $-0.46 | ||
| Q2 24 | $0.13 | $-0.30 | ||
| Q1 24 | $0.26 | $-0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $466.2M |
| 总债务越低越好 | $604.2M | — |
| 股东权益账面价值 | $1.2B | $370.1M |
| 总资产 | $2.2B | $1.1B |
| 负债/权益比越低杠杆越低 | 0.50× | — |
8季度趋势，按日历期对齐
现金及短期投资AESIAPLS
| Q4 25 | — | $466.2M | ||
| Q3 25 | — | $479.2M | ||
| Q2 25 | — | $370.0M | ||
| Q1 25 | — | $358.4M | ||
| Q4 24 | — | $411.3M | ||
| Q3 24 | — | $396.9M | ||
| Q2 24 | — | $360.1M | ||
| Q1 24 | — | $325.9M |
总债务AESIAPLS
| Q4 25 | $604.2M | — | ||
| Q3 25 | $529.1M | — | ||
| Q2 25 | $533.8M | — | ||
| Q1 25 | $538.5M | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $180.0M | — | ||
| Q2 24 | $180.0M | — | ||
| Q1 24 | $180.0M | $93.1M |
股东权益AESIAPLS
| Q4 25 | $1.2B | $370.1M | ||
| Q3 25 | $1.2B | $401.2M | ||
| Q2 25 | $1.3B | $156.3M | ||
| Q1 25 | $1.3B | $164.2M | ||
| Q4 24 | $1.0B | $228.5M | ||
| Q3 24 | $1.0B | $237.1M | ||
| Q2 24 | $1.1B | $264.3M | ||
| Q1 24 | $1.1B | $266.7M |
总资产AESIAPLS
| Q4 25 | $2.2B | $1.1B | ||
| Q3 25 | $2.2B | $1.1B | ||
| Q2 25 | $2.2B | $821.4M | ||
| Q1 25 | $2.3B | $807.3M | ||
| Q4 24 | $2.0B | $885.1M | ||
| Q3 24 | $2.0B | $901.9M | ||
| Q2 24 | $2.0B | $904.5M | ||
| Q1 24 | $1.9B | $831.9M |
负债/权益比AESIAPLS
| Q4 25 | 0.50× | — | ||
| Q3 25 | 0.43× | — | ||
| Q2 25 | 0.42× | — | ||
| Q1 25 | 0.41× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.17× | — | ||
| Q2 24 | 0.17× | — | ||
| Q1 24 | 0.17× | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.7M | $-14.2M |
| 自由现金流经营现金流 - 资本支出 | $-18.1M | $-14.3M |
| 自由现金流率自由现金流/营收 | -7.3% | -7.1% |
| 资本支出强度资本支出/营收 | 8.7% | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-30.9M | $45.0M |
8季度趋势，按日历期对齐
经营现金流AESIAPLS
| Q4 25 | $3.7M | $-14.2M | ||
| Q3 25 | $32.4M | $108.5M | ||
| Q2 25 | $88.6M | $4.4M | ||
| Q1 25 | $-7.5M | $-53.4M | ||
| Q4 24 | $70.9M | $19.4M | ||
| Q3 24 | $85.2M | $34.1M | ||
| Q2 24 | $60.9M | $-8.3M | ||
| Q1 24 | $39.6M | $-133.0M |
自由现金流AESIAPLS
| Q4 25 | $-18.1M | $-14.3M | ||
| Q3 25 | $-1.4M | $108.3M | ||
| Q2 25 | $48.4M | $4.4M | ||
| Q1 25 | $-59.8M | $-53.4M | ||
| Q4 24 | $-5.6M | $19.3M | ||
| Q3 24 | $-1.1M | — | ||
| Q2 24 | $-54.9M | $-8.4M | ||
| Q1 24 | $-55.9M | $-133.3M |
自由现金流率AESIAPLS
| Q4 25 | -7.3% | -7.1% | ||
| Q3 25 | -0.5% | 23.6% | ||
| Q2 25 | 16.8% | 2.5% | ||
| Q1 25 | -20.1% | -32.0% | ||
| Q4 24 | -2.1% | 9.1% | ||
| Q3 24 | -0.4% | — | ||
| Q2 24 | -19.1% | -4.2% | ||
| Q1 24 | -29.0% | -77.3% |
资本支出强度AESIAPLS
| Q4 25 | 8.7% | 0.1% | ||
| Q3 25 | 13.0% | 0.0% | ||
| Q2 25 | 13.9% | 0.0% | ||
| Q1 25 | 17.6% | 0.0% | ||
| Q4 24 | 28.2% | 0.0% | ||
| Q3 24 | 28.3% | 0.0% | ||
| Q2 24 | 40.3% | 0.0% | ||
| Q1 24 | 49.6% | 0.2% |
现金转化率AESIAPLS
| Q4 25 | — | — | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | — | ||
| Q1 25 | -6.11× | — | ||
| Q4 24 | 4.92× | — | ||
| Q3 24 | 21.74× | — | ||
| Q2 24 | 4.10× | — | ||
| Q1 24 | 1.48× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AESI
| Services | $126.2M | 51% |
| Products | $105.2M | 42% |
| Moser Acquisition | $18.1M | 7% |
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
